Pruritus: An update

Current Problems in Dermatology

Volumn 15, Issue 4, 2003, Pages 135-164

  Jorizzo, Joseph L ^a   Yosipovitch, Gil ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; ANTIPRURITIC AGENT; BILE ACID RESIN; CAPSAICIN; CORTICOSTEROID; CYTOKINE; EMOLLIENT AGENT; ERYTHROPOIETIN; HETASTARCH; HISTAMINE; IMMUNOMODULATING AGENT; LEUKOTRIENE; NEUROPEPTIDE; OPIATE ANTAGONIST; OPIATE PEPTIDE; PRIMROSE OIL; PROSTAGLANDIN; RIFAMPICIN; SEROTONIN; SEROTONIN 3 ANTAGONIST; STRONTIUM NITRATE; THALIDOMIDE; TRYPTASE; UNCLASSIFIED DRUG;

ANOREXIA NERVOSA; AUTOIMMUNE DISEASE; BRACHIORADIAL PRURITUS; BULLOUS SKIN DISEASE; BURN; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE CLASSIFICATION; DRUG INDUCED PRURITUS; ENDOCRINE DISEASE; HEMATOPOIETIC DISEASE; HEPATIC PRURITUS; HEPATOBILIARY DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; HYPERTROPHIC SCAR; HYPOTHYROIDISM; KELOID; LICHEN AMYLOIDOSUS; LICHENOID ERUPTION; MULTIPLE SCLEROSIS; NERVE CONDUCTION; NERVE STIMULATION; NEUROGENIC PRURITUS; NEUROPATHIC PRURITUS; NEUROPATHIC PRUTITUS; NOTALGIA PARESTHETICA; PAPULAR SKIN DISEASE; PATHOPHYSIOLOGY; PHANTOM PRURITUS; PHOTOTHERAPY; POSTHERPETIC PRURITUS; POSTINFLAMMATORY HYPERPIGMENTATION; PREGNANCY; PRURIGO; PRURIGO NODULE; PRURITUS; PSORIASIS; PSYCHOGENIC PRURITUS; REVIEW; SJOEGREN SYNDROME; SKIN DISEASE; SKIN NERVE; SLEEP DISORDER; THYROID DISEASE; UREMIC PRURITUS; VAGUS NERVE STIMULATION; VEIN INSUFFICIENCY; XEROSIS;

EID: 0042244185     PISSN: 10400486     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (204)

1. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003;361:690-4.
2. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, et al. Itch: scratching more than the surface. Quart J Med 2003;96:7-26.
3. Koblenzer CS. Psychologic and psychiatric aspects of itching. In: Bernhard JD, editor. Itch mechanisms and management of pruritus. New York: McGraw Hill; 1994. p. 352-65.
4. Yosipovitch G, Greaves MW. Itch definitions. In: Yosipovitch G, Greaves MW, McGlone F, Fleischer AB, editors. Itch basic mechanisms and therapy. New York: Mercel Dekker. In press.
5. Simone DA, Alreja M, LaMotte RH. Psychophysical studies of the itch sensation and itchy skin (Aalloknesis) produced by intracutaneous injection of histamine. Somatosens Mot Res 1991;8:271-9.
6. Heyer G, Ulmer FJ, Schmitz J, Handwerker HO. Histamine-induced itch and alloknesis (itchy skin) in atopic eczema patients and controls. Acta Derm Venereol 1995;75:348-52.
7. Fleischer AB. The clinical management of itching. 2000. New York: Parthenon Publishing.
8. Felix R, Shuster S. A new method for the measurement of itch and the response to treatment. Br J Dermatol 1975;93:303-12.
9. Ebata T, Aizawa H, Kamide R. An infrared video camera system to observe nocturnal scratching in atopic dermatitis patients. J Dermatol 1996;23:153-5.
10. Yosipovitch G, Xiong GL, Haus E, Sackett-Lundeen L, Ashkenazi I, Maibach HI. Time-dependent variations of the skin barrier function in humans: transepidermal water loss, stratum corneum hydration, skin surface pH, and skin temperature. J Invest Dermatol 1998;110:20-3.
11. Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002;11:12-24.
12. Yosipovitch G, Reis J, Tur E, Sprecher E, Yarnitsky D, Boner G. Sweat secretion, stratum corneum hydration, small nerve function and pruritus in patients with advanced chronic renal failure. Br J Dermatol 1995;133:561-4.
13. Kato A, Hamada M, Maruyama T, Maruyama Y, Hishida A. Pruritus and hydration state of stratum corneum in hemodialysis patients. Am J Nephrol 2000;20:437-42.
14. Beauregard S, Gilchrest BA. A survey skin problems and skin care regimens in the elderly. Arch Dermatol 1987;123:1638-43.
15. Yosipovitch G. Epidemiology of itch. In: Yosipovitch G, Greaves MW, McGlone F, Fleischer AB, editors. Itch basic mechanisms and therapy. New York: Mercel Dekker. In press.
16. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
17. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000;143:969-73.
18. Black MM, Jones EW. Macular amyloidosis. A study of 21 cases with special reference to the role of the epidermis in its histogenesis. Br J Dermatol 1971;84:199.
19. Ganor S, Dollberg L. Amyloidosis of the nipple presenting as pruritus. Cutis 1983;31:318.
20. Gorodeski IG, Cordoba M, Shapira A, Bahary CM. Primary localized cutaneous lichen amyloidosus of the vulva. Int J Dermatol 1988;27:259-60.
21. Weyers W, Weyers I, Bonczkowitz M, Diaz-Cascajo C, Schill WB. Lichen amyloidosus: a consequence of scratching. J Am Acad Dermatol 1997;37:923-8.
22. Yap KB, Siew MG, Goh CL. Pattern of skin diseases in the elderly seen at the National Skin Center. Singapore Med J 1994;35:147-50.
23. Herman LE. Itching in scars. In: Bernhard J, editor. Itch mechanisms and management of pruritus. New York: McGraw Hill; 1994. p. 153-60.
24. Head MD. Wound and skin care. In: Fisher SV, Helm PA, editors. Comprehensive rehabilitation of burns. Baltimore: Williams and Wilkins; 1984. p. 173.
25. Klotki J, Pochon JP. Conservative treatment using compression suits for second and third degree burns in children. Burns 1982;8:180-7.
26. Herndon DN, LeMaster J, Beard S, Bernstein N, Lewis SR, Rutan TC, et al. The quality of life after minor thermal injury in children: an analysis of 12 survivors with >80% total body, 70% third-degree burns. J Trauma 1986;26:609-17.
27. Ward RS, Saffle JR, Schnebly A, Hayes-Lundy C, Reddy R. Sensory loss over grafted areas in patients with burns. J Burn Care Rehabil 1989;10:536-8.
28. Vitale M, Fields-Blache C, Luterman A. Severe itching in the patient with burns. J Burn Care Rehabil 1991;12:330-3.
29. Blalock SJ, Bunker BJ, Moore JD, Foreman N, Walsh JF. The impact of burn injury: a preliminary investigation. J Burn Care Rehabil 1992;13:487-92.
30. Malenfant A, Forget R, Papillon J, Amsel R, Frigon J-Y, Choiniere M. Prevalence and characteristics of chronic sensory problems in burn patients. Pain 1996;67:493-500.
31. Barnden L, Griffiths T, Littiard K, Sperring B. Burns patients and itching. Aust N Z Burn Assoc Bull 1998;22:3-5.
32. Tyack ZF, Ziviani J, Pegg S. The functional outcome of children after a burn injury: a pilot study. J Burn Care Rehabil 1999;20:367-73.
33. Peloro TM, Miller OF, Hahn TF, Newman ED. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol 2001;45:28-34.
34. Feuerman EJ. Sjögren's syndrome presenting as recalcitrant generalized pruritus. Some remarks about its relation to collagen diseases and the connection of rheumatoid arthritis with the Sicca syndrome. Dermatologica 1968;137:74-86.
35. Aso K. Senile dry skin type Sjögren's syndrome. Int J Dermatol 1994;33:351-5.
36. Renula T. Dermatitis herpetiformis. Clin Dermatol 2001;19:728-36.
37. Allan SJ, Tidman MJ. Pemphigoid excoriee: a further variant of bullous pemphigoid. Br J Dermatol 1999;141:585-6.
38. Barnadas MA, Pujol RM, Curell R, Matias-Guiu X, Alomar A. Generalized pruritic eruption with suprabasal acantholysis preceding the development of bullous pemphigoid. J Cutan Pathol 2000;27:96-8.
39. World Health Organization. WHO fact sheets on onchoreciasis N-95. 2000.
40. Gelfand JM, Rudikoff D. Evaluation and treatment of itching in HIV-infected patients. Mt Sinai J Med 2001;68:298-308.
41. Rodwell G, Berger T. Pruritus and cutaneous inflammatory conditions in HIV disease. Clin Dermatol 2000;18:479-84.
42. Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ. Chemokines and glycoprotein 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001;21:5027-35.
43. Herzberg U, Sagen J. Peripheral nerve exposure to HIV viral envelope protein gp 120 induces neuropathic pain and spinal gliosis. J Neuroimmunol 2001;116:29-39.
44. Burton JL, Holden CA. Eczema, lichenification and prurigo. In: Champion RH, Burton JL, Burns DA, Brethnach SM, editors. Rook/Wilkinson and Ebling textbook of dermatology, 6th ed. Oxford, UK: Blackwell Science; 1998. p. 629-60.
45. Black MM. Polymrophic eruption of pregnancy. In: Black M, McKay M, et al, editors. Obstetric and gynecologic dermatology. St Louis: Mosby; 2002:p.39-44.
46. Nurse DS. Prurigo of pregnancy. Australas J Dermatol 1968;9:849-55.
47. Zoberman E, Farmer ER. Pruritic folliculitis of pregnancy. Arch Dermatol 1981;117:20-2.
48. Liddell K. Post-herpetic pruritus. Br Med J 1974;4:165.
49. Darsow U, Lorenz J, Bromm B, Ring J. Pruritus circumscriptus sine materia: a sequel of postzosteric neuralgia. Evaluation by quantitative psychophysical examination and laser-evoked potentials. Acta Derm Venereol 1996;76:45-7.
50. Oaklander AL, Cohen SP, Raju SVY. Intractable postherpetic itch and cutaneous deafferenation after facial shingles. Pain 2002;96:9-12.
51. Sugeng MW, Yosipovitch G, Leok GC. Postherpetic neuralgia and the dermatologist. Int J Dermatol 2001;40:6-11.
52. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 1997;136:553-9.
53. Murphy M, Carmichael AJ, Lawler PG, White M. The incidence of hydroxyethyl starch-associated pruritus. Br J Dermatol 2001;144:973-6.
54. Stander S, Bone HG, Machens HG, Aberle T, Burchard W, Prien T, et al. Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals. Cell Tissue Res 2002;310:279-87.
55. Massey EW, Pleet AB. Localized pruritus-notalgia paresthetica. Arch Dermatol 1979;115:982-3.
56. Bernhard JD. Notalgia paresthetica, macular posterior pigmentary incontinence, macular amyloidosis and pruritus. Acta Derm Venereol 1997;77:164.
57. Raison-Peyron N, Meunier L, Acevedo M, Meynadier J. Notalgia paresthetica: clinical, physiopathological and therapeutic aspects. A study of 12 cases. J Eur Acad Dermatol Venerol 1999;12:215-21.
58. Savk E, Savk O, Bolukbasi O, Culhaci N, Dikcioglu E, Karaman G, et al. Notalgia paresthetica: a study on pathogenesis. Int J Dermatol 2000;39:754-9.
59. Eisenberg E, Barmeir E, Bergman R. Notalgia paresthetica associated with nerve root impingement. J Am Acad Dermatol 1997;37:998-1000.
60. Wallengren J. Brachioradial pruritus: a recurrent solar dermopathy. J Am Acad Dermatol 1998;39:803-6.
61. Fisher DA. Brachioradial pruritus wanted: a sure cause (and cure) for brachioradial pruritus. Int J Dermatol 1997;36:817-8.
62. Kavak A, Dosoglu M. Can a spinal tumor be a causative factor of brachioradial pruritus? J Am Acad Dermatol 2002;46:437-40.
63. Massey EW, Massey JM. Forearm neuropathy and pruritus. South Med J 1986;79:1259-60.
64. Goodkin R, Wingard E, Bernhard J. Brachioradial pruritus: cervical spine disease and neurogenic pruritus. J Am Acad Dermatol 2003;48:521-4.
65. Heyl T. Brachioradial pruritus. Arch Dermatol 1983;119:115-6.
66. Johnson RE, Kanigsberg ND, Jimenez CL. Localized pruritus: a presenting symptom of a spinal cord tumor in a child with features of neurofibromatosis. J Am Acad Dermatol 2000;43:958-61.
67. Bernhard JD. Editor's comment. J Am Acad Dermatol 1999;41:658.
68. King CA, Huff FJ, Jorizzo JL. Unilateral neurogenic pruritus: paroxysmal itching associated with central nervous system lesions. Ann Intern Med 1982;97:222-3.
69. Shapiro PE, Braun CW. Unilateral pruritus after a stroke. Arch Dermatol 1987;123:1527-30.
70. Massey EW. Unilateral neurogenic pruritus following stroke. Stroke 1984;15:901-3.
71. Canavero S, Bonicalzi V, Massa-Micon B. Central neurogenic pruritus: a literature review. Acta Neurol Belg 1997;97:244-7.
72. Summers GC, MacDonald JT. Paroxysmal facial itch: a presenting sign of childhood brainstem glioma. J Child Neurol 1988;3:189-92.
73. Andreev VC, Petkov I. Skin manifestations associated with tumours of the brain. Br J Dermatol 1975;92:675-8.
74. Sullivan MJ, Drake ME. Unilateral pruritus and Nocardia brain abscess. Neurology 1984;34:828-9.
75. Shabtai H, Nispeanu P, Chapman J, Korczyn AD. Pruritus in Creutzfeldt-Jacob disease. Neurology 1996;46:940-1.
76. Lierman LM. Phantom breast experiences after mastectomy. Oncol Nurs Forum 1988;15:41-4.
77. Nail L, Jones LS, Guiffre M, Jognson JE. Sensations after mastectomy. Am J Nurs 1984;84:1121-4.
78. Jacome D. Phantom itching relieved by scratching phantom feet. JAMA 1978;240:2432.
79. Bernhard JD. Phantom itch, pseudophantom itch, and senile pruritus. Int J Dermatol 1992;31:856-7.
80. Matthews WB, Compston A, Allen IV, Martin CN. McAlpine's multiple sclerosis. Edinburgh: Churchill-Livingstone; 1991, p. 68.
81. Osterman PO, Westerberg C-E. Paroxysmal attacks in multiple sclerosis. Brain 1975;98:189-202.
82. Yamamoto M, Yabuki S, Hayabara T. Paroxysmal itching in multiple sclerosis: a report of three cases. J Neurol Neurosurg Psychiatry 1981;44:19-22.
83. Sandyk R. Paroxysmal itching in multiple sclerosis during treatment with external magnetic fields. Int J Neurosci 1994;75:65-71.
84. Bergasa NV, Jones EA. The pruritus of cholestasis: potential pathogenic and therapeutic implications for opioids. Gastroenterology 1995;108:1582-8.
85. Botero F. Pruritus as a manifestation of systemic disorders. Cutis 1978;21:873-80.
86. Prince MI, Jones DE. Primary biliary cirrhosis: new perspectives in diagnosis and treatment. Postgrad Med J 2000;76:199-206.
87. Chia SC, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, Di Bisceglie AM. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 1998;10:2177-83.
88. Franco J. Pruritus. Curr Treat Options Gastroenterol 1999;2:451-6.
89. Schwartz IF, Iaina A. Management of uremic pruritus. Semin Dial 2000;13:177-80.
90. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus: new perspectives and insights from recent trials. Nephrol Dial Transplant 2002;17:1558-63.
91. Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 2001;115:619-21.
92. Gerlini G, Prignano F, Pimpinelli N. Acute leucocytoclastic vasculitis and aquagenic pruritus long preceding polycythemia rubra vera. Eur J Dermatol 2002;12:270-1.
93. Gobbi PG, Attardo-Parrinello G, Lattanzio G, Rizzo SC, Ascari E. Severe pruritus should be a B symptom in Hodgkin's disease. Cancer 1983;15:1934-6.
94. Adams SJ. Iron deficiency and other hematological causes of generalized pruritus. In: Bernhard JD. Itch mechanisms and management of pruritus. New York: McGraw Hill. 1994, p. 243-50.
95. Caravati CM Jr, Richardson DR, Wood BT, Cawley EP. Cutaneous manifestations of hyperthyroidism. South Med J 1969;62:1127-30.
96. Zirwas MJ, Seraly MP. Pruritus of unknown origin: a retrospective study. J Am Acad Dermatol 2001;45:892-6.
97. Morgan JF, Lacey JH. Scratching and fasting: a study of pruritus and anorexia nervosa. Br J Dermatol 1999;140:453-6.
98. Litt J. Pocket book of drug eruptions and interactions. 1999. New York: Parthenon Publishing.
99. Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs 2001;15:351-9.
100. Fried RG. Evaluation and treatment of psychogenic pruritus and self-excoriation. J Am Acad Dermatol 1995;32:532-3.
101. Koo JY, Gambla C. Delusions of parasitosis and other forms of monsymptomatic hypochondriasis. Dermatol Clin 1996;14:429-38.
102. Melamed Y, Yosipovitch G. Itch as a focus of mental disease. In: Yosipovitch G, Greaves MW, McGlone F, Fleischer AB, editors. Itch basic mechanisms and therapy. New York: Mercel Dekker. In press.
103. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjork HE. Specific C receptors for itch in human skin. J Neurosci 1997;17:8003-8.
104. Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001;4:72-7.
105. Hsieh JC, Hagermark O, Stahle-Backdahl M, Ericson K, Eriksson L, Stone-Elander S, et al. Urge to scratch represented in the human cerebral cortex. J Neurophysiol 1994;72:3004-8.
106. Darsow U, Drzezga A, Frisch M, Munz F, Weilke F, Bartenstein P, et al. Processing of histamine-induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. J Invest Dermatol 2000;115:1029-33.
107. Drzezga A, Darsow U, Treede RD, Siebner H, Frisch M, Munz F, et al. Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain 2001;92:295-305.
108. Rukwied R, Howard M, Hitchcock D, McGlone F. Histamine induced discriminative and affective responses revealed by functional MRI. In: Yosipovitch G, Greaves MW, McGlone F, Fleischer AB, editors. Itch basic mechanisms and therapy. New York: Mercel Dekker. In press.
109. Hägermark Ö, Hökfelt T, Pernow B. Flare and itch induced by substance P in human skin. J Invest Dermatol 1978;71:233-5.
110. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, et al. Acute effects of substance P and calcitonin gene-related peptide in human skin: a microdialysis study. J Invest Dermatol 2000;115:1015-20.
111. Suzuki R, Furuno T, McKay DM, Wolvers D, Teshima R, Nakanishi M, et al. Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol 1999;163:2410-5.
112. Hagermark O. Itch mediators. Semin Dermatol 1995;14:271-6.
113. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000;6:151-8.
114. Jarvikallio A, Naukkarinen A, Harvima IT, Aalto ML, Horsmanheimo M. Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br J Dermatol 1997;136:871-7.
115. Steinhoff M, Corvera CU, Thoma MS, Kong W, McAlpine BE, Caughey GH, et al. Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol 1999;8:282-94.
116. Hägermark O. Peripheral and central mediators of itch. Skin Pharmacol 1992;5:1-8.
117. Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002;435:259-64.
118. Bigliardi-Qi M, Bigliardi PL, Eberle AN, Buchner S, Rufli T. β-Endorphin stimulates cytokeratin 16 expression and down regulates m-opiate receptor expression in human epidermis. J Invest Dermatol 2000;114:527-32.
119. Friedman JD, Dello Buone FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother 2001;35:85.
120. Weisshaar E, Ziethen B, Gollnick H. Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch? Inflamm Res 1997;46:412.
121. Weisshaar E, Ziethen B, Gollnick H. The antipruritic effect of a 5-HT3 receptor antagonist (tropisetron) is dependent on mast cell depletion: an experimental study. Exp Dermatol 1999;8:254.
122. Jones EA, Bergsa NV. The pruritus of cholestasis. Hepatology 1999;29:1003-6.
123. Wahlgren CF, Tengvall Linder M, Hagermark O, Scheynius A. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res 1995;287:572-80.
124. Moraes M, Russo G. Thalidomide and its dermatologic uses. Am J Med Sci 2001;321:321-6.
125. Greaves MW, McDonald-Gibson W. Itch: role of prostaglandins. Br Med J 1973;22:608-9.
126. Andoh T, Katsube N, Maruyama M, Kuraishi Y. Involvement of leukotriene B(4) in substance P-induced itch-associated response in mice. J Invest Dermatol 2001;117:1621-6.
127. Yosipovitch G, David M. The diagnostic and therapeutic approach to idiopathic generalized pruritus. Int J Dermatol 1999;38:881-7.
128. Woodall TG, Kantor GR. Pruritus. Current Problems Dermatol 2000:14-6.
129. Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the AEppendorf Itch Questionnaire. Int Arch Allergy Immunol 2001;124:326-31.
130. Yosipovitch G, Zucker I, Boner G, Gafter U, Shapira Y, David M. A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol 2001;81:108-11.
131. Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrum Technol 1991;25:400-3.
132. Endo K, Sumitsuji H, Fukuzumi T, Adachi J, Aoki T. Evaluation of scratch movements by a new scratch-monitor to analyze nocturnal itching in atopic dermatitis. Acta Derm Venereol 1997;77:432-5.
133. Ebata T, Iwasaki S, Kamide R, Niimura M. Use of a wrist activity monitor for the measurement of nocturnal scratching in patients with atopic dermatitis. Br J Dermatol 2001;144:305-9.
134. Wahlgren CF. Measurement of itch. Semin Dermatol 1995;14:277-84.
135. Freitag G, Hoppner T. Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin. Curr Med Res Opin 1997;13:529-37.
136. Yosipovitch G, Szolar C, Hui XY, Maibach H. Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin. Arch Dermatol Res 1996;288:245-8.
137. Bromm B, Scharein E, Darsow U, Ring J. Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci Lett 1995;187:157-60.
138. Yosipovitch G, Maibach HI. Effect of topical pramoxine on experimentally induced pruritus in humans. J Am Acad Dermatol 1997;37:278-80.
139. Shuttleworth D, Hill S, Marks R, Connelly DM. Relief of experimentally induced pruritus with a novel eutectic mixture of local anaesthetic agents. Br J Dermatol 1988;119:535-40.
140. Layton AM, Cotterill JA. Notalgia paraesthetica: report of three cases and their treatment. Clin Exp Dermatol 1991;16:197-8.
141. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol 1994;31:613-6.
142. Shelley WB, Shelley ED, Talanin NY. Self potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J Am Acad Dermatol 1996;34:143-4.
143. Reimann S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001;44:471-8.
144. Yosipovitch G, Maibach HI, Rowbotham MC. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. Acta Derm Venereol 1999;79:118-21.
145. Cheer SM, Plosker GL. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001;2:389-406.
146. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002;62:817-40.
147. Fleischer AB. Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Allergy Clin Immunol 1999;104:S126-30.
148. Daly BM, Shuster S. Effect of aspirin on pruritus. Br Med J 1986;293;907.
149. Yosipovitch G, Ademola J, Lui P, Amin S, Maibach HI. Topically applied aspirin rapidly decreases histamine induced itch. Acta Derm Venereol 1997;77:46-8.
150. Yosipovitch G, Sugeng MW, Chan YH, Goon A, Ngim S, Goh CL. The effect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol 2001;45:910-3.
151. Miller MJ, Vergnolle N, McKnight W, Musah RA, Davison CA, Trentacosti AM, et al. Inhibition of neurogenic inflammation by the Amazonian herbal medicine sangre de grado. J Invest Dermatol 2001;117:725-30.
152. Zhai H, Hannon W, Hahn GS, Harper RA, Pelosi A, Maibach HI. Strontium nitrate decreased histamine-induced itch magnitude and duration in man. Dermatology 2000;200:244-6.
153. Hahn GS. Strontium is a potent and selective inhibitor of sensory irritation. Dermatol Surg 1999;25:689-94.
154. Lebwohl M. Phototherapy of pruritus. In: Bernhard JD, editor. Itch: mechanisms and management of pruritus. New York: McGraw-Hill; 1994. p. 399-411.
155. Krause L, Shuster S. Mechanisms of action of antipruritic drugs. Br Med J 1983;287:1199-200.
156. Daly BM, Shuster S. Antipruritic action of thalidomide. Acta Derm Venereol 2000;80:24-5.
157. Goodless DR, Eaglstein WH. Brachioradial pruritus: treatment with topical capsaicin. J Am Acad Dermatol 1993;29:783-4.
158. Knight TE, Hayashi T. Solar (brachioradial) pruritus-response to capsaicin cream. Int J Dermatol 1994;33:206-9.
159. Bueller HA, Bernhard JB, Dubroff LM. Gabapentin treatment for brachioradial pruritus. J Eur Acad Dermatol Venerol 1999;13:227-30.
160. Tait CP, Grigg E, Quirk CJ. Brachioradial pruritus and cervical spine manipulation. Australas J Dermatol 1998;39:168-70.
161. Rongioletti F. Pruritus as presenting sign of cervical rib. Lancet 1992;339:55.
162. Taylor RS. Multiple sclerosis potpourri. Paroxysmal symptoms, seizures, fatigue, pregnancy, and more. Phys Med Rehabil Clin N Am 1998;9:551-9.
163. Goulden V, Toomey PJ, Highet AS. Successful treatment of notalgia paresthetica with a paravertebral local anesthetic block. J Am Acad Dermatol 1998;38:114-6.
164. Layton AM, Cotterill JA. Notalgia paresthetica: report of three cases and their treatment. Clin Exp Dermatol 1991;16:197-8.
165. Wallengren J. Treatment of notalgia paresthetica with topical capsaicin. J Am Acad Dermatol 1991;24:286-8.
166. Sandroni P. Central neuropathic itch: a new treatment option? Neurology 2002;59:778-80.
167. Bernstein JE, Swift RM. Relief of intractable pruritus with naloxone. Arch Dermatol 1979;115:1366.
168. Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal disease and dermatological diseases. J Am Acad Dermatol 1999;41:533-9.
169. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102:544-9.
170. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995;123:161-7.
171. Ständer S, Metze D. Treatment of pruritus in internal and dermatological diseases with opioid receptor antagonists. In: Yosipovitch G, Greaves MW, McGlone F, Fleischer AB, editors. Itch basic mechanisms and therapy. New York: Mercel Dekker. In press.
172. Bertolotti M, Ferrari A, Vitale G, Stefani M, Trenti T, Loria P, et al. Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J Hepatol 1997;27:505-11.
173. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998;27:679-84.
174. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999;41:431-4.
175. Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001;13:1393-4.
176. Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, et al. Randomized crossover trial of naltrexone in uraemic pruritus. Lancet 1996;348:1552-4.
177. Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, et al. Naltrexone does not relieve uremic pruritus: results of randomized, placebo controlled crossover-study. J Am Soc Nephrol 2000;11:514-9.
178. Kumagai H, Sasamura H, Hayashi M, et al. Prospects for a novel opioid kappa receptor agonist TRK 820 in uremic pruritus [abstract]. In: Yosipovitch G, editor. Proceedings of the International Workshop for the Study of Itch, October 5-7, 2001; Singapore. p. 59.
179. Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002;435:259-64.
180. Carey JB. Lowering of serum bile acid concentrations and relief of pruritus in jaundiced patients fed a bile acid sequestering resin. J Lab Clin Med 1960;56:797-8.
181. Silverberg DS, Iaina A, Reisin E, Rotzak R, Eliahou HE. Cholestyramine in uraemic pruritus. Br Med J 1977;1:752-3.
182. Thompson W. Cholestyramine. Can Med Assoc J 1971;104:305-9.
183. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988;94:488-93.
184. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989;1:574-6.
185. Kreek MJ. Rifampicin-induced methadone withdrawal. N Engl J Med 1979;294:1104-6.
186. Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother 1994;33:387-401.
187. Schwörer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Invest 1993;71:659-62.
188. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865-70.
189. Raderer M, Müller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med 1994;330:1540.
190. Balaskas EV, Bamihas GI, Karamouzis M, Voyiatzis G, Tourkantonis A. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 1998;78:395-402.
191. Larijani GE, Goldberg ME, Rogers KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. Pharmacotherapy 1996;16:958-60.
192. Ashmore SD, Jones CH, Newstead CG, Daly MJ, Chrystin H. Ondansetron therapy for uremic patients in hemodialysis. Am J Kidney Dis 2000;35:827-31.
193. Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001;18:346-57.
194. Murphy M, Reaich D, Pai P, Finns P, Carmichael AJ. A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2001;145(Suppl 59):20.
195. De Marchi S, Cecchin E, Villalta D, Sepiacci G, Santini G, Bartoli E. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 1992;326:969-74.
196. Balaskas EV. Erythropoietin treatment does not improve uremic pruritus. Perit Dial Int 1992;12:330-1.
197. Yoon S, Lee J, Lee S. The therapeutic effect of evening primrose oil in atopic dermatitis patients with dry scaly skin lesions is associated with the normalization of serum gamma-interferon levels. Skin Pharmacol Appl Skin Physiol 2002;15:20-5.
198. Yoshimoto-Furuie K, Yoshimoto K, Tanaka T, Saima S, Kikuchi Y, Shay J, et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron 1999;81:151-9.
199. Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain 1997;71:49-55.
200. Wallengren J, Sundler F. Cutaneous field stimulation in the treatment of severe itch. Arch Dermatol 2001;137:1323-5.
201. Kirchner A, Stefan H, Schmelz M, Haslbeck KM, Birklein F. Influence of vagus nerve stimulation on histamine induced itching. Neurology 2002;59:108-12.
202. Gupta MA, Gupta AK. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol 2001;15:512-8.
203. Koo J, Lee CS. Delusions of parasitosis. A dermatologist's guide to diagnosis and treatment. Am J Clin Dermatol 2001;2:285-90.
204. Fried RG. Nonpharmacologic treatments in psychodermatology. Dermatol Clin 2002;20:177-85.